Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, su…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06661720
Sites in Virginia: - Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Richmond Community Hospital — Richmond, Virginia
- Bon Secours Saint Mary's Hospital — Richmond, Virginia
- Virginia Cancer Institute — Richmond, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Virginia: - VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 2 Recruiting Academic/Other
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with re…
Sponsor: NRG Oncology
NCT ID: NCT05327686
Sites in Virginia: - Inova Alexandria Hospital — Alexandria, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
- Bon Secours Cancer Institute at Reynolds Crossing — Richmond, Virginia
Phase 2 Recruiting Network
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Dru…
Sponsor: Children's Oncology Group
NCT ID: NCT04322318
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
- Carilion Children's — Roanoke, Virginia
Phase 1, Phase 2 Recruiting Industry
This study is testing a new medicine called PF-08634404 and how it works in adults with advanced Renal Cell Carcinoma (RCC)- a type of kidney cancer that is either locally advanced (spread to nearby tissues) or metastatic (spread to other …
Sponsor: Pfizer
NCT ID: NCT07227415
Sites in Virginia: - Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Blacksburg, Virginia
- Virginia Cancer Specialists, PC — Fairfax, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Low Moor, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Roanoke, Virginia
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care — Salem, Virginia
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT03972657
Sites in Virginia: - Emily Couric Clinical Cancer Center — Charlottesville, Virginia
Phase 1, Phase 2 Recruiting Industry
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Sponsor: AstraZeneca
NCT ID: NCT07115043
Sites in Virginia: - Research Site — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Virginia: - Exelixis Clinical Site #66 — Charlottesville, Virginia
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Virginia: - NEXT Oncology Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a Phase 1b, open-label, multicenter, safety, tolerability and efficacy study of HC-7366 in combination with belzutifan (WELIREG™). This is a multipart study that consists of a HC-7366 monotherapy cohort, a combination dose escalati…
Sponsor: HiberCell, Inc.
NCT ID: NCT06234605
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either di…
Sponsor: Nuvectis Pharma, Inc.
NCT ID: NCT05873686
Sites in Virginia: - NEXT Oncology Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study of NEO-811 for subjects with locally advanced or metastatic non-resectable clear cell renal cell carcinoma. The study will test NEO-811 i…
Sponsor: Neomorph, Inc
NCT ID: NCT07300241
Sites in Virginia: - NEO-811 Virginia Site — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study …
Sponsor: Pliant Therapeutics, Inc.
NCT ID: NCT06270706
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Sponsor: Novelty Nobility, Inc.
NCT ID: NCT06805825
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1 Recruiting Industry
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 a…
Sponsor: Sairopa B.V.
NCT ID: NCT05856981
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1 Recruiting Industry
This is a Phase 1a/1b, first-in-human (FIH), multi-center, open-label, non-randomized, dose escalation study, designed to determine the Maximum tolerated dose(MTD)/Recommended Phase 2 dose (RP2D) and to evaluate safety, tolerability, preli…
Sponsor: LG Chem
NCT ID: NCT06332755
Sites in Virginia: - NEXT Oncology — Fairfax, Virginia
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Virginia: - Chesapeake Regional Medical Center — Chesapeake, Virginia
- Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Bon Secours Memorial Regional Medical Center — Mechanicsville, Virginia
- Bon Secours Westchester Emergency Center — Midlothian, Virginia
- Bon Secours Saint Francis Medical Center — Midlothian, Virginia
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Children's Hospital of The King's Daughters — Norfolk, Virginia
- Naval Medical Center - Portsmouth — Portsmouth, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Virginia: - Massive Bio SYNERGY-AI site — Charlottesville, Virginia
Recruiting Academic/Other
Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (\<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications…
Sponsor: Azienda Ospedaliero-Universitaria Careggi
NCT ID: NCT05363657
Sites in Virginia: - VCU Health System — Richmond, Virginia